glp 1 trump administration Novo Nordisk, Lilly strike deal with to slash weight-loss drug prices Trump administration makes deal to

The scientists compared people who got GLP-1 drugs for their diabetes with people who got drugs that use a different mechanism to control blood sugar levels

Pauling This Pharmacology Consult will focus on GLP-1 receptor agonists that are currently FDA approved for weight loss, including semaglutide (Wegovy, Novo Nordisk) and liraglutide (Saxenda, Novo Nordisk), but other FDA-approved options exist, such as orlistat, naltrexone/bupropion and phentermine/topiramate

Available from: Sandra Christensen 1 , Katie Robinson 2 , Sara Thomas 2 , Dominique R Williams 2 Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs

These medicines are marketed under different names depending on the indication and country, including: Semaglutide: Ozempic, Wegovy Tirzepatide: Mounjaro, Zepbound However, the research is still developing